Lunsumio (mosunetuzumab-axgb) vs Columvi (glofitamab-gxbm)
Lunsumio (mosunetuzumab-axgb) vs Columvi (glofitamab-gxbm)
Lunsumio (mosunetuzumab-axgb) and Columvi (glofitamab-gxbm) are both innovative monoclonal antibodies used in the treatment of certain types of B-cell non-Hodgkin lymphoma, but they have distinct mechanisms of action and dosing regimens. Lunsumio is a bispecific T-cell engager that brings T-cells into proximity with cancer cells to enhance the immune response, whereas Columvi is a dual-affinity retargeting molecule that binds to both CD20 on B-cells and CD3 on T-cells. When deciding which medicine is right for an individual, it is crucial to consult with a healthcare professional who can evaluate the specific medical condition, treatment history, potential side effects, and the latest clinical evidence to make an informed recommendation.
Difference between Lunsumio and Columvi
| Metric | Lunsumio (mosunetuzumab-axgb) | Columvi (glofitamab-gxbm) |
|---|---|---|
| Generic name | Mosunetuzumab-axgb | Glofitamab-gxbm |
| Indications | Relapsed or refractory follicular lymphoma | Relapsed or refractory B-cell non-Hodgkin lymphoma |
| Mechanism of action | CD20xCD3 T-cell engaging bispecific antibody | CD20xCD3 T-cell engaging bispecific antibody |
| Brand names | Lunsumio | Columvi |
| Administrative route | Intravenous infusion | Intravenous infusion |
| Side effects | Cytokine release syndrome, infections, fatigue, etc. | Cytokine release syndrome, neutropenia, pyrexia, etc. |
| Contraindications | None specifically listed; use caution in patients with infections, cytopenias, etc. | None specifically listed; use caution in patients with infections, cytopenias, etc. |
| Drug class | Bispecific monoclonal antibody | Bispecific monoclonal antibody |
| Manufacturer | Genentech, Inc. | Genentech, Inc. |
Efficacy
Lunsumio (mosunetuzumab-axgb) Efficacy in Treating Lymphoma
Lunsumio, with the generic name mosunetuzumab-axgb, is a bispecific antibody designed to target CD20 on B cells and CD3 on T cells, thereby engaging the body's immune system to fight against lymphoma cells. In clinical trials, Lunsumio has shown promising efficacy in the treatment of several types of B-cell non-Hodgkin lymphoma (NHL), including relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). The treatment has been particularly beneficial for patients who have exhausted other treatment options, such as chemotherapy and stem cell transplantation.
One of the pivotal studies for Lunsumio's efficacy was a phase I/II trial that demonstrated a complete response rate in a significant proportion of patients with relapsed or refractory B-cell NHL. The results indicated that Lunsumio could induce durable responses, with many patients maintaining their response for extended periods. The therapy has been hailed for its potential to offer a new line of treatment for those who have limited options due to the progression of their disease.
Columvi (glofitamab-gxbm) Efficacy in Treating Lymphoma
Columvi, also known as glofitamab-gxbm, is another bispecific antibody that targets CD20 on B cells and CD3 on T cells, similar to Lunsumio. Columvi has shown efficacy in clinical trials for patients with relapsed or refractory B-cell lymphomas, including DLBCL. Its mechanism of action, which involves redirecting T cells to engage and eliminate B-cell lymphoma cells, has been effective in producing high response rates in patients who have previously been treated with multiple lines of therapy.
Key clinical trials for Columvi have reported encouraging response rates, with a subset of patients achieving complete remission. The data suggest that Columvi has the potential to become a valuable therapeutic option for individuals with aggressive and hard-to-treat lymphomas. As with Lunsumio, the durability of responses to Columvi is an area of active investigation, with ongoing studies aiming to better understand the long-term benefits and optimal use of this therapy in the lymphoma treatment landscape.
Regulatory Agency Approvals
Lunsumio
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Columvi
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Lunsumio or Columvi today
If Lunsumio or Columvi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us